AGC Biologics buys Boulder AstraZeneca plant
BOULDER — After sitting idle for nearly a year, a new tenant is set to take over the shuttered AstraZeneca PLC plant in Boulder.
AstraZeneca inked a deal in late 2019 to sell the pharmaceutical plant to Japanese contract drug maker AGC Biologics. That deal was completed in late May and the parties recorded a joint tenancy warranty deed with Boulder County last week worth nearly $40 million.
The facility is expected to begin full-scale operations and manufacturing by April 2021, according to an AGC news release.
“The addition of this facility supports AGC…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
The U.S. Department of Energy is ponying up $10 million for Prometheus Materials Inc., a…
-
Fortius Metals Inc. has raised an additional $2 million, bringing the total haul for the…
-
Real estate professionals are eligible to earn seven continuing-education credits at the 17th annual Boulder…
-
Lawrence Yun, chief economist for the National Association of Realtors, will keynote the 17th annual…
